Clinical Trial Update: Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of mogamulizumab (KW-0761) for CCR4-positive Peripheral T/NK-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Mogamulizumab (mogamulizumab)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Peripheral T/NK-cell Lymphoma | Phase 2 | Status: COMPLETED